How well does Vonjo(Pacritinib) work?

The efficacy of VONJO was established in a clinical trial focusing on spleen volume reduction in a high-risk patient population.

Clinical Efficacy

In the PERSIST-2 clinical trial, VONJO demonstrated significant efficacy in reducing spleen volume. For patients with a baseline platelet count below 50 × 10⁹/L, 29.0% of those treated with VONJO 200 mg twice daily achieved a ≥35% reduction in spleen volume at Week 24, compared to only 3.1% of patients receiving best available therapy. The median reduction in spleen volume was 27.3% for the VONJO group, substantiating its therapeutic effect in this specific myelofibrosis patient subgroup.